Regeneron could see share price bounce with potential approvals


Stock market data with uptrend vector


An upcoming FDA action date for Regeneron Pharmaceuticals’ (NASDAQ:REGN) rare immune disease candidate, pozelimab, could lead to a significant boost in the biopharma’s stock price according to one analyst.

The action date is this Sunday, Aug. 19. Because the date falls on a

Source link

Leave A Reply

Your email address will not be published.